New hope for chinese MG patients: ravulizumab trial targets daily symptom relief
NCT ID NCT07596784
First seen May 22, 2026 · Last updated May 23, 2026 · Updated 1 time
Summary
This study tests a drug called ravulizumab in 20 Chinese adults with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. The goal is to see if the drug improves daily activities and muscle strength over 26 weeks. Participants must have a specific antibody and meet severity criteria. The drug works by blocking part of the immune system, so patients need a meningococcal vaccine before starting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.